Abstract
Breast cancer therapy involves a multidisciplinary approach com-prising surgery, radiotherapy, neoadjuvant and adjuvant therapy. Effective therapy of breast cancer requires maximum therapeutic efficacy, with mini-mal undesirable effects to ensure a good quality of life for patients. The carefully selected combination of therapeutic interventions provides patients with the opportunity to derive maximum benefit from therapy while minimiz-ing or eliminating recurrence, resistance and toxic effects, as well as ensuring that patients have a good quality of life. This review discusses therapeutic op-tions for breast cancer treatments and various combinations that had been previously exploited. The review will also give an insight into the potential application of the nanotechnology platform for co-delivery of therapeutics in breast cancer therapy.
Highlights
Breast cancer (BC) is the most commonly occurring cancer in women and represents the leading cause of death associated with cancer among females globally [1, 2]
The results indicated that addition of gemcitabine to anthracycline and taxane-based adjuvant chemotherapy at the dose and schedule of the trial did not confer a therapeutic advantage in terms of diseasefree survival in early-stage breast cancer (EBC), it could result in increased toxicity [90]
Combination therapy offers the potential of improving therapeutic efficacy and efficiency in BC treatment
Summary
Breast cancer (BC) is the most commonly occurring cancer in women and represents the leading cause of death associated with cancer among females globally [1, 2]. Key: BL = Basal-like; LA = Luminal-A; LB = Luminal-B; HER2+ = Human epidermal growth factor 2 (HER2)-positive/HER2-enriched/HER2-overexpressing BC; NL = Normal-like tumors. Amongst the molecular subtypes of BC, HER2-positive and basal-like subtypes are associated with aggressive disease and poor outcomes [6, 7, 12] and Luminal B tumors show remarkably worse prognosis than Luminal A tumors, which have frequently shown better outcomes than the other subtypes [4, 6]. Basal-like BC on the other hand, which is negative for the HRs (ER or PgR receptors) and HER2 does not present a therapeutic target and so would not be expected to derive benefit from endocrine or molecularly targeted therapy [6, 7]. It is not intended to be an exhaustive review on the subject
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
